TB-500 (Thymosin Beta-4)

TB-500 | Thymosin Beta-4 Fragment | Research Peptide

Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln Molecular Formula: C₂₁₂H₃₅₀N₅₆O₇₈S Molecular Weight: 4963.44 g/mol Purity: >99% (HPLC verified) Form: Lyophilised powder Available Sizes: 5mg | 10mg Storage: –20°C, away from light and moisture CAS Number: 77591-33-4

---

What Is TB-500?

TB-500 is a synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in virtually all human and animal cells. TB-500 corresponds to the active region of Thymosin Beta-4 — specifically the actin-binding domain — which is widely considered to be the peptide's primary site of biological activity in preclinical models.

Thymosin Beta-4 was first isolated from bovine thymus tissue in the early 1980s and has since become one of the most studied members of the beta-thymosin family. TB-500, as the synthetic research variant, allows scientists to investigate the specific mechanisms attributed to Tβ4's active sequence without the complexity of working with the full protein.

Our TB-500 is manufactured under stringent quality-controlled conditions, achieving a verified purity of greater than 99% as confirmed by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). It is supplied as a lyophilised (freeze-dried) powder to maximise stability during storage and shipping.

---

Research Background & Scientific Interest

TB-500 has been the subject of a significant and growing body of preclinical literature, with research spanning multiple disciplines including cellular biology, cardiovascular science, orthopaedics, and ophthalmology. Its primary mechanism of action centres on its ability to bind G-actin — a monomeric form of actin — thereby influencing cell migration, proliferation, and differentiation.

Actin Sequestration & Cell Motility The most well-characterised property of Thymosin Beta-4 and its analogues is G-actin sequestration. By binding to actin monomers, TB-500 regulates the dynamic polymerisation of the actin cytoskeleton. This action is understood to play a central role in cell migration and has made the compound of considerable interest in wound healing and tissue remodelling research.

Tissue Repair & Wound Healing Models TB-500 has been extensively studied in preclinical wound healing models. Research in rodent models has explored its influence on keratinocyte migration, dermal repair, and angiogenic signalling. Studies have demonstrated accelerated wound closure in animal models, attributed in part to the upregulation of key repair-associated proteins including VEGF (vascular endothelial growth factor) and matrix metalloproteinases (MMPs).

Cardiovascular & Cardiac Research Some of the most compelling TB-500 preclinical data has emerged from cardiovascular research. Studies in animal cardiac injury models — including myocardial infarction — have investigated Thymosin Beta-4's influence on cardiomyocyte survival, angiogenesis, and cardiac progenitor cell activation. Researchers have observed cardioprotective responses and promotion of vasculogenesis in ischaemic tissue models, making this a particularly active area of investigation.

Musculoskeletal & Connective Tissue Research TB-500 has attracted substantial interest in musculoskeletal research contexts. Preclinical studies have explored the peptide in models of tendon, ligament, and muscle injury, with findings suggesting modulation of inflammatory markers and support for extracellular matrix remodelling. Its apparent influence on skeletal muscle satellite cell activation has also been a focus of recent in vitro studies.

Anti-inflammatory Activity Research has indicated that Thymosin Beta-4 may modulate NF-κB signalling — a master regulator of inflammatory gene expression. Preclinical studies have observed downregulation of pro-inflammatory cytokines including TNF-α and IL-1β in relevant models, suggesting a potential role in resolving acute and chronic inflammation that warrants continued scientific investigation.

Neurological Research An emerging area of TB-500 research concerns neuroregeneration. Early-stage preclinical studies have examined the peptide's effects in models of brain injury, spinal cord trauma, and neuroinflammation, with some findings pointing to neuroprotective and oligodendrocyte-promoting activity. This remains an exploratory frontier requiring further rigorous study.

---

Product Specifications

---

Quality & Purity Assurance

Every batch of our TB-500 is subject to a comprehensive quality control process before it reaches researchers. Our assurance pipeline includes:

• HPLC Analysis — confirms peptide purity exceeding 99%
• Mass Spectrometry (MS) — verifies molecular identity, sequence accuracy, and molecular weight
• Endotoxin Testing — ensures the product is free from bacterial endotoxins
• Certificate of Analysis (CoA) — available for every batch upon request

We maintain full traceability across our manufacturing and testing process, so researchers can rely on batch-to-batch consistency for reproducible experimental outcomes.

---

Handling & Reconstitution (Research Use)

TB-500 lyophilised powder should be reconstituted using sterile bacteriostatic water or phosphate-buffered saline (PBS), depending on the experimental protocol. Gently swirl — do not vortex — to avoid disrupting peptide integrity. Once reconstituted, aliquot immediately and store at –20°C. Avoid repeated freeze-thaw cycles, as these can compromise peptide stability and reduce experimental reliability.

All handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.

---

How TB-500 Compares to BPC-157

Researchers frequently study TB-500 and BPC-157 in parallel due to their overlapping areas of preclinical interest — particularly tissue repair and inflammation modelling. While BPC-157 is gastric in origin and primarily studied via the nitric oxide and growth hormone receptor pathways, TB-500 acts principally through actin sequestration and VEGF-mediated angiogenesis. Their distinct mechanisms make them complementary subjects in multi-peptide research protocols, and both are available in our catalogue.

---

Important Notice

This product is intended strictly for in vitro research and laboratory use only. TB-500 is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.